IMPORTANCE Strategies to prevent autism in children exposed to antiepileptic drugs (AEDs) during pregnancy are important.
C hildren exposed to antiepileptic drugs (AEDs) during pregnancy have an increased risk of autistic traits. [1] [2] [3] [4] [5] Autistic traits include impairment of social skills and communication as well as stereotyped or repetitive behavior or interests. 6 These traits represent the core symptoms in autism spectrum disorders and often coexist with other neuropsychiatric diseases. Embryotoxic mechanisms and geneenvironmental interactions are probably essential causes of autism. 7, 8 Genetic polymorphisms in folate metabolic pathways are associated with autism. 9 In the general population, periconceptional folic acid supplements reduce the risk of autism spectrum disorders. 10, 11 However, to our knowledge, no previous studies have investigated whether this reduced risk also applies to children of women using AEDs. Several AEDs interfere with folate absorption and metabolism. 12,13 Thus, the risk of folate deficiency in pregnancy is higher among women with epilepsy than among healthy women. 14 Low-dose folic acid supplements (0.4 mg/d) in the periconceptional period reduce the risk of spina bifida in the general population 15 and are recommended for all women. 16 High-dose folic acid supplements (5.0 mg/d) are recommended before pregnancy in female AED users, 17 but the effect of such treatment is uncertain. 12 For women in general, folic acid supplementation with doses greater than 5.0 mg/d had a negative effect on child psychomotor development. 18 In mothers using AEDs, use of folic acid supplements has been associated not only with a higher rate of congenital malformations 19,20 but also with higher child IQ. 21 The aim of this study was to test the a priori hypothesis that folic acid supplements and maternal folate concentration in pregnancy are associated with modified frequency and degree of autistic traits in children exposed to AEDs in utero.
Methods

Study Population
The Norwegian Mother and Child Cohort Study (MoBa) is a prospective, population-based, long-term cohort study conducted by the Norwegian Institute of Public Health. 22 From June 1999 through December 31, 2008, most pregnant women in Norway received postal invitations, with a participation rate of 41% (95 267 women). 22 No exclusion criteria were applied except inability to read Norwegian. Follow-up conducted by regular questionnaires is ongoing. The mothers completed questionnaires during gestational weeks 17 to 19 (Q1) and 30 (Q2) and at child ages 18 months (Q3) (response rate, 72.8%) and 36 months (Q4) (response rate, 56.1%) and an epilepsy-specific follow-up questionnaire in 2013 (Q5). The present study is based on version 8 of the quality-assured data files of the MoBa. The study was approved by the Norwegian Data Inspectorate and the Regional Committee for Medical Research Ethics. Written informed consent was obtained from the mothers. Supplementary clinical information was obtained through a database linkage to the mandatory Medical Birth Registry of Norway. 23 Diagnostic information, including generalized tonicclonic seizures during pregnancy, AED dose, and folic acid dose, was obtained from Q5. Seizure occurrence during pregnancy reported by the women was confirmed by hospital records in 75% of the cases, and seizure-free status was confirmed in 89%. 24 We included children for whom information concerning their mothers' use of folic acid supplements and/or plasma folate concentration during pregnancy was available (90.2%). Our study group included children of women with reported epilepsy and AED use during pregnancy (n = 335) ( Figure 1) . The MoBa epilepsy cohort has been validated and described previously. 24 With use of the International League Against Epilepsy criteria, 25 our hospital case file review in a geographical subsample (7.5%) confirmed the diagnosis in 100% of women with reported epilepsy and AED use. Plasma concentration analyses confirmed AED use as reported by 238 of 256 mothers, yielding a positive predictive value for reported AED use of 93.0%. All children of mothers without reported epilepsy served as a reference group (n = 104 222). Children of women with reported epilepsy but no AED intake during pregnancy served as an internal control group (n = 389) ( Figure 1 ). Blood samples in this group were not analyzed for AEDs, but none of the patients had any AED use registered in the Medical Birth Registry of Norway. In this group, 127 (70.9%) reported inactive epilepsy defined as not using AEDs during the 2 years before conception or no seizures during the previous 5 years. 
AED Use
Folic Acid Supplementation
Folic acid supplement use before conception and in gestational weeks 0 to 4, 5 to 8, 9 to 12, and 13 or more was reported in Q1 and at gestational weeks 13 to 16, 17 to 20, 22 to
Key Points
Question Is folic acid supplementation associated with reduced risk of autistic traits in children exposed to antiepileptic drugs in utero?
Findings This population-based cohort and Norwegian biobank study that included 104 946 children found that children exposed to antiepileptic drugs in utero had a significantly lower risk of autistic traits if the mother used periconceptional folic acid supplements. Maternal plasma folate concentration in gestational weeks 17 to 19 was inversely associated with the degree of autistic traits.
Meaning Risk of autistic traits in children exposed to antiepileptic drugs in utero may be mitigated by periconceptional folic acid supplementation and folate status.
24, 25 to 28, and 29 or more in Q2. Periconceptional intake was defined as use of a folic acid supplement from 4 weeks before to 12 weeks after conception. Use of high-dose folic acid (>0.4 mg/d) was reported by 84 of 139 mothers with epilepsy taking AEDs (60.4%). In this group, 17 (20.2%) used polytherapy, 4 (4.8%) including valproate (eMethods 2 in the Supplement).
Laboratory Analyses
Blood samples were obtained during gestational weeks 17 to 19 and from the umbilical cord immediately after delivery and sent to the MoBa Biobank (eMethods 3 in the Supplement).
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In women with epilepsy using AEDs (n = 229), the plasma samples from gestational weeks 17 to 19 were analyzed for the biologically active 5-methyltetrahydrofolate (mTHF), the degradation products 4-α-hydroxy-mTHF (hmTHF), p-aminobenzoylglutamate (pABG), p-acetamidobenzoylglutamate (apABG), and unmetabolized folic acid by liquid chromatography tandem mass spectrometry (eMethods 3 in the Supplement). 27 The prevailing folate form in plasma is mTHF, which is not stable at room temperature but can be largely recovered as hmTHF. 28 Plasma folate concentrations are therefore given as the sum of mTHF and hmTHF levels. The maternal samples from gestational weeks 17 to 19 and the umbilical cord plasma samples (n = 198) were analyzed for AED concentrations and calculated as mean levels, as described elsewhere. 24 In short, carbamazepine, carbamazepine-10, 11-epoxide, the oxcarbazepine monohydroxy derivative metabolite, lamotrigine, levetiracetam, and topiramate were analyzed with liquid chromatography mass spectrometry. Valproate was analyzed by a commercially available kit (Cobas Integra 400 Plus System; Roche Diagnostics).
Outcome Measurements
Autistic traits in the children were investigated with the Modified Checklist for Autism in Toddlers (M-CHAT) at 18 months of age and the Social Communication Questionnaire (SCQ) at 36 months of age, as previously reported. 5 The instruments are based on parent-reported measures focusing on behavior that deviates from normal social development (eTables 1 and 2 in the Supplement). Children aged 16 to 30 months who missed any 3 of 23 items or 2 of 6 critical items in the M-CHAT are at risk of having autism spectrum disorders. 29 For estimating autism spectrum disorders at 10 years of age using the M-CHAT administered in the same age group and with the same criteria as in our study, the sensitivity was 0. 
Covariates
The following covariates in the logistic regression analysis were chosen based on relevance for development of autism spectrum disorders 8 Fisher exact test used if any cross-table cell had an expected count of less than 5. Risk estimates were calculated as odds ratios (ORs) with 95% CIs using logistic multivariable regression analysis. The primary measures of association were the crude OR and the adjusted OR (AOR) for autistic traits in children of women with vs without periconceptional use of folic acid supplements. Calculations were performed separately (stratified) for women with epilepsy and AED use during pregnancy, women with epilepsy and no AED use during pregnancy, and women without epilepsy. A second predefined key outcome was the dose-response association between maternal plasma concentrations of folate and the degree of autistic symptoms analyzed with multivariable linear regression analyses (mean SCQ score) and Spearman rank correlation coefficient (mean M-CHAT score). Residual plots were inspected to ensure that assumptions concerning normal distribution of the residuals were met.
Results
The overall mean (SD) maternal age of the 104 946 mothers of participating children was 29.8 (4.6) years. Complete demographic information was available for analysis in 103 868 mothers. Demographic and clinical information is reported in Table 1 .
Folic Acid Supplementation and Risk of Autistic Traits in the Offspring
Among children aged 18 months and exposed to AEDs, the AOR for autistic traits if the mother did not use folic acid supplements was 5.9 (95% CI, 2.2-15.8) compared with use of supplements ( Table 2 ). The corresponding AOR for children aged 36 months was 7.9 (95% CI, 2.5-24.9). In women without epilepsy, the corresponding AORS were 1.3 (95% CI, 1.2-1.4) at 18 months of age and 1.7 (95% CI, 1.5-1.9) at 36 months of age, and the CIs did not overlap those in the AED group (Table 2) . In children of mothers with untreated epilepsy not taking folic acid supplements compared with children of mothers who took supplements, no significant risk of autistic traits was found at 18 months of age (AOR, 1.0; 95% CI, 0.4-3.0) and 36 months of age (AOR, 2.5; 95% CI, 0.4-16.6).
Plasma Folate and Degree of Autistic Traits
In AED-exposed children, an inverse association existed between mean SCQ score and maternal plasma folate concentration during gestational weeks 17 to 19 ( Figure 2 and eTable 3intheSupplement). The quartile with the lowest folate concentrations had a higher SCQ score than the quartile with the highest folate concentrations (eTable 4 in the Supplement). Ad hoc analyses adjusted for confounding factors similarly showed an inverse linear association between mean SCQ score and folic acid supplement dose (discrete variable according to intake as registered by the women: 0.4, 1.0, 2.0, or ≥4.0 mg/d) at all times during pregnancy. The association was most pronounced for first trimester folic acid supplementation ( β=− 0 . 4 5 ;P < .001) (eFigure 1 in the Supplement). Total M-CHAT score was associated with the folic acid supplement dose before pregnancy (ρ = −0.2; P = .01) and in the first trimester (ρ = −0.3; P = .004), but not with plasma folate concentration (eFigure 2 in the Supplement). No difference in median M-CHAT scores across the quartiles of folate concentrations was apparent. Antiepileptic drug concentration (eTable 5 and eFigure 3 in the Supplement), AED dose, number of generalized tonic-clonic seizures, unmetabolized folic acid concentration, and the concentration of the folate degradation products pABG and apABG were not associated with degree of autistic traits.
Timing of Folic Acid Intake
In the AED-exposed group, mothers of children with autistic traits were less likely to have used folic acid supplements in pregnancy weeks 0 to 12 than mothers of children without autistic traits ( Figure 3) . Frequency of mothers using folic acid supplements after week 12 was similar between groups. Median time for starting supplementation was gestational week 6.5 for mothers of children with autistic traits at 18 months of age and week 12.5 for those with autistic traits at 36 months of age. In contrast, mothers of children without autistic traits more frequently started folic acid supplementation before pregnancy (median, preconceptional week 1) compared with mothers of children with autistic traits at 18 months of age (median, 6.5 weeks; P = .007) and at 36 months of age (median, 12.5 weeks; P = .01). Median supplementation start time did not differ between mothers of children with and without autistic traits among those not using AEDs (Figure 3) . In a post hoc analysis, we subdivided the AED-exposed cohort into groups with autistic traits at 18 and 36 months of age (n = 4 [group 1]), autistic traits at one age but not the other (n = 35 [group 2]), or no autistic traits at either age (n = 184 [group 3]). In the AED-exposed group, the rate of maternal periconceptional folic acid use was 0 in group 1, 37.1% (13 mothers) in group 2, and 53.3% (98 mothers) in group 3; the median start of folic acid supplementation was gestational week 15 in group 1, gestational week 7 in group 2, and before conception in group 3 (eTable 6 in the Supplement).
Type of AED
The association of periconceptional folic acid supplement use with the risk of autistic traits in AED-exposed children appeared to exist across all AEDs (eFigure 4 in the Supplement).
In the valproate subgroup (n = 38), 4 (12.9%) had autistic traits at 18 and/or 36 months if the mother used folic acid supplements, compared with 2 (28.6%) in the group with mothers who did not use supplements (P = .19). A post hoc analysis investigating the association of the interaction between AEDs and folic acid supplement intake with the number of autistic traits showed that this interaction was highly significant (B = −3.1; SE = 1.1; β = −0.42; P = .004) (eFigure 5 in the Supplement).
Discussion
Mothers using an AED during pregnancy hada5to8times increased risk of having a child with autistic traits if they did not use folic acid in the periconceptional period. Without periconceptional folic acid supplementation, 1 in 3 children exposed to AEDs had autistic traits at 18 and 36 months of age. Moreover, the maternal plasma concentration of folate during gestational weeks 17 to 18 was inversely associated with the degree of autistic traits at 3 years of age. For children who were not exposed to AEDs during pregnancy, the risk for autistic traits was only slightly increased if the mother did not use folic acid supplements in the periconceptional period. The association was present regardless of AED type.
The main finding of our study is in line with the results of an uncontrolled study of 105 children exposed to AEDs in pregnancy 2 in whom lack of folic acid supplementation in the first trimester seemed to be associated with autistic traits. Our data demonstrate the critical importance of an early start of folic acid 
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supplement intake. In the group of mothers with children developing autistic traits, fewer women had used folic acid supplements before and until week 13 of pregnancy compared with those with children without autistic traits. The proportion using folic acid later in pregnancy was similar between the 2 groups. The critical importance of folic acid supplementation early in pregnancy is supported by studies of autism spectrum disorders in the general population. 11 Folic acid intake before pregnancy and until gestational weeks 4 to 8 was associated with a reduced risk of autism in the child. 10, 35 Supplementation later in pregnancy did not have a protective effect. 10 These findings match the 20-to 40-day postconception time frame hypothesized to be critical for the development of autism spectrum disorders during pregnancy, at days 20 to 40 after conception. 7, 36 We found an inverse association between maternal plasma folate concentration at gestational weeks 17 to 19 and the degree of autistic traits at 3 years of age. This association should reflect folate status also at the critical point 20 to 40 days after conception, because folate has a half-life of approximately 100 days. 37 We also demonstrated an inverse association between the degree of autistic traits and folic acid dose, especially during the first trimester. Supplementation timing represents a clinical challenge, because pregnancies may not be recognized until after the period when folate status is critical. In patients with epilepsy, 24% to 79% of pregnancies are unintended.
34, 38 We therefore recommend that folic acid supplements be used continuously by all women taking AEDs who could become pregnant.
Strengths and Limitations
This prospective, population-based, controlled, but observational study was derived from a single cohort. Studies from other cohorts are needed. In particular, the effect of folic acid supplements on autism in the child should be studied in different AED treatment groups with sufficient statistical power to evaluate specific monotherapy and polytherapy cohorts. The validity of the selfreported exposure variables was confirmed by biological measurements. We controlled for relevant confounding factors. Parental rating of autistic traits may represent a limitation compared Percentages of folic acid supplement use in pregnancy in mothers giving birth to a child with and without autistic traits at 18 and 36 months of age. Median start and withdrawal times for supplementation are shown as lines under the graphs. Among mothers of antiepileptic drug (AED)-exposed children, mothers of children with autistic traits started folic acid supplementation significantly later (range, 16-31 weeks) than mothers of children without autistic features at 18 months of age (P = .007) and 36 months of age (P = .01).
a P < .05.
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with a clinically based diagnostic evaluation. However, questionnaires completed by parents provide information about children that reflect a wider range of dysfunction after AED exposure. 3 The stability of the results with different rating instruments (SCQ and M-CHAT) and across different child ages (18 and 36 months) strengthens our findings. The positive predictive value for autistic disorders from a screening tool for autism ranges from 10% to 60% for young children at low risk recruited from the community. 30, 39 However, the specificity is high, and most children with positive screening results will have autistic traits in the frame of a developmental disorder even if they do not fulfill all the criteria for an autism disorder. 30, [39] [40] [41] [42] In our study, we have therefore focused on autistic traits, not autistic disorders. We did not reveal significant associations between AED plasma concentrations or doses and autistic traits. Data on concentrations of AEDs during pregnancy in association with child outcome are sparse. The neutral association in our study is in line with a population-based study that found no difference in risk regarding autism spectrum disorders in children of mothers using a high dose (>750 mg/d) vs a low dose (≤750 mg/d) of valproate.
1 Another study found a dose effect of valproate on risk for autistic traits. 2 The mean daily valproate sodium dose used in the MoBa epilepsy cohort was 754 mg/d (range, 200-1200 mg/d), 24 which is lower than reported by clinic-based studies. 2, 21 For some of the AEDs, statistical power was low. Thus, the neutral association between AED load and autistic traits must be interpreted with caution.
Conclusions
Folic acid supplementation in early pregnancy is associated with a reduced risk of autistic traits in children of mothers with epilepsy using AEDs. The benefit of folic acid supplements was not restricted to children exposed to valproate. Folic acid intake was critical during the first 12 gestational weeks. We detected a dose-effect association for the degree of autistic traits. Unplanned pregnancies are common in the epilepsy cohort, and folic acid supplements should be taken continuously by all women taking AEDs if they could become pregnant. Polytherapy combinations involving lamotrigine were found in 13 %, levetiracetam in 8 %, carbamazepine in 6 %, oxcarbazepine in 6 %, valproate in 5 %, topiramate in 2 %, clonazepam in 2 % and vigabatrin in 1 %.
eMethods 3. Biobank Analysis of Blood Samples and Folate
The samples were centrifuged within 30 minutes after collection and stored at 4 o C until they were sent to the MoBa Biobank at the Norwegian Institute of Public Health{Paltiel, 2014 #147;Paltiel, 2014 #147}. Within 2 days after sampling plasma samples were aliquoted and kept at -80 o C until delivery for antiepileptic drug and folate analysis, respectively.
For the folate analyses, the limits of quantification were 0.13, 0.40, 0.17, 0.27, and 0.53 nmol/L for mTHF, hmTHF, pABG, apABG and folic acid, respectively. The assay was linear for all analytes up to 140 nmol/L, and the coefficients of variation were < 10 %. 
